Centaurus Financial, Inc. Galectin Therapeutics Inc Transaction History

Centaurus Financial, Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Dec 05, 2022	SELL	$1.31 - $2.48 $281 - $533	-215 Reduced 1.03%	20,732 $34,000
Q2 2022 Aug 02, 2022	SELL	$1.19 - $1.74 $198 - $290	-167 Reduced 0.79%	20,947 $27,000
Q1 2022 May 13, 2022	BUY	$1.61 - $2.31 $33,993 - $48,773	21,114 New	21,114 $34,000
Q4 2021 Feb 01, 2022	SELL	$2.07 - $3.8 $46,810 - $85,933	-22,614 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$2.59 - $4.15 $18,130 - $29,050	7,000 Added 44.83%	22,614 $88,000
Q2 2020 Aug 13, 2020	BUY	$1.66 - $3.15 $685 - $1,300	413 Added 2.72%	15,614 $48,000
Q1 2020 Apr 21, 2020	SELL	$1.51 - $3.0 $93 - $186	-62 Reduced 0.41%	15,201 $30,000
Q3 2019 Nov 12, 2019	SELL	$3.0 - $4.05 $3,900 - $5,265	-1,300 Reduced 7.85%	15,263 $56,000
Q2 2019 Aug 15, 2019	BUY	$3.61 - $5.0 $59,496 - $82,405	16,481 Added 20098.78%	16,563 $69,000
Q1 2019 Jul 01, 2019	SELL	$3.86 - $6.02 $61,941 - $96,602	-16,047 Reduced 99.49%	82 $16.1 Million
Q1 2019 May 13, 2019	BUY	$3.86 - $6.02 $62,257 - $97,096	16,129 New	16,129 $82,000
Q4 2018 Feb 12, 2019	SELL	$3.43 - $5.74 $34 - $57	-10 Closed	0 $0
Q3 2018 Nov 05, 2018	SELL	$3.68 - $6.93 $61,463 - $115,744	-16,702 Reduced 99.94%	10 $60,000
Q2 2018 Aug 15, 2018	BUY	$3.16 - $9.16 $21,209 - $61,481	6,712 Added 67.12%	16,712 $106,000
Q4 2017 Feb 09, 2018	BUY	$1.54 - $3.34 $15,400 - $33,400	10,000	10,000 $33,000

10M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.1M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.